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Infectious and sterile inflammatory diseases are
correlated with increased levels of high mobility
group box 1 (HMGB1) in tissues and serum. Extracel-
lular HMGB1 is known to activate Toll-like receptors
(TLRs) 2 and 4 and RAGE (receptor for advanced
glycation endproducts) in inflammatory conditions.
Here, we find that TLR5 is also an HMGB1 receptor
that was previously overlooked due to lack of func-
tional expression in the cell lines usually used for
studying TLR signaling. HMGB1 binding to TLR5
initiates the activation of NF-kB signaling pathway
in a MyD88-dependent manner, resulting in proin-
flammatory cytokine production and pain enhance-
ment in vivo. Biophysical and in vitro results highlight
an essential role for the C-terminal tail region of
HMGB1 in facilitating interactions with TLR5. These
results suggest that HMGB1-modulated TLR5 sig-
naling is responsible for pain hypersensitivity.INTRODUCTION
The hallmark of almost all pathogenic infections or tissue injuries
involves a primary host inflammatory response mediated by
receptors of the innate immune system (Mogensen, 2009).
Increasing evidence suggests that theCNS alsomounts an orga-
nized innate immune response during systemic infection and
neuronal injuries caused by various diseases (Aravalli et al.,
2007; Muzio et al., 2007). When peripheral nerves are damaged,
neurotransmitters, neuropeptides, and cellular debris initiate an
innate immune response that drives peripheral and central sensi-
tization, subsequently causing chronic pain (Grace et al., 2014;
Ren and Dubner, 2010).
Toll-like receptors (TLRs) are important components of the
innate immune system that regulate detection of pathogen-
associated molecular patterns (PAMPs) and damage-associ-
ated molecular patterns (DAMPs; a.k.a. ‘‘alarmins’’) (Akira and1128 Cell Reports 17, 1128–1140, October 18, 2016 ª 2016 The Auth
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type I transmembrane proteins localized either at the plasma
membrane (TLRs 1, 2, 4–6, and 10) or within the endosomal
compartment (TLRs 3 and 7–9), protecting the host against
threats present in either the extracellular or intracellular environ-
ment (Akira and Takeda, 2004). In sterile brain injury (Liesz et al.,
2011) and neuropathic pain (Tanga et al., 2005; Kim et al., 2007),
TLR2- and TLR4-mediated proinflammatory signaling plays a
pivotal role in orchestrating the response to neural traumas.
In CNS damage, DAMPs, such as nucleic acids, high mobility
group box 1 (HMGB1), and S100 proteins are passively released
from necrotic brain cells. These DAMPs bind to cell-surface
TLRs of microglia, the first responder resident immune cell of
the CNS (Takeuchi and Akira, 2010; Grace et al., 2014). Once
activated, microglia transition to a state of reactive gliosis,
release high levels of a wide array of proinflammatory mediators
that can exacerbate tissue damage, and stimulate the recruit-
ment of peripheral immune cells, such as neutrophils and mono-
cytes/macrophages, to the site of injury (Ren and Dubner, 2010;
Liesz et al., 2015). Similar proinflammatory cascades follow pe-
ripheral tissue and nerve injuries (Watkins et al., 2007). Together,
peripheral and central immune responses induce neuroinflam-
matory cascades, which can exacerbate the initial injury as
collateral damage (Watkins et al., 2007).
HMGB1 is a non-histone nuclear protein that is well known to
bind to DNA and stabilize DNA interactions with transcription
factors to regulate gene transcription (Goodwin et al., 1973).
HMGB1 has recently emerged as a DAMP that can activate
innate and adaptive immunity and drive host inflammatory re-
sponses (Lotze and Tracey, 2005). Release of HMGB1 from
necrotic cells into the extracellular milieu is a primary driver of
alarmin-mediated inflammatory responses across many model
systems (Kim et al., 2006, Park et al., 2006). In contrast to
the retention of HMGB1 within the nucleus of healthy cells,
HMGB1 is released into the extracellular space surrounding
necrotic and pyroptotic cells upon acetylation of its lysine resi-
dues that are present at nuclear localization sequence (NLS)
sites (Scaffidi et al., 2002). HMGB1 can then either act alone in
initiating immune signaling or can bind to, and act in concert
with, other inflammatory proteins (e.g., interleukin 1b [IL-1b]),or(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Activation of TLR5 by HMGB1
(A) TLR ligands activate SEAP signaling in HEK cells. WT, TLR2-, TLR4-, and
TLR5-overexpressing HEK cells were incubated with TLR ligands, HMGB1,
or AGE-BSA for 24 hr. NF-kB activation was evaluated by SEAP secretion in
the culture supernatant by the QUANTI-Blue SEAP reporter assay. See also
Figure S1A.
(B) RAW 264.7 cells were incubated with TLR ligands or HMGB1, AGE-BSA,
and anti-RAGE NAb for 24 hr. oxPAPC was added at varying doses. NF-kB-
driven iNOS activation was evaluated by the NO produced. All data are pre-
sented as mean ± SD; n = 3. *p < 0.05 (unpaired Student’s t test) relative to
untreated cells.thereby increasing their combined inflammatory properties
(M€uller et al., 2001).
Previous studies suggest that HMGB1 released from necrotic
cells can signal through three cell-surface receptors: receptor for
advanced glycation endproducts (RAGE), TLR2, and TLR4 (Hori
et al., 1995; Park et al., 2004). These receptors are ubiquitously
expressed on cells of peripheral nerves and tissues and can co-
ordinate diverse responses to insults (Farina et al., 2005; Mishra
et al., 2006). While multiple prior studies have identified the role
of TLR2 and TLR4 in pain amplification via actions at peripheral
nerve terminals and/or the spinal cord (Qi et al., 2011), the work
of Ji and colleagues raised the possibility that TLR5 is involved
in pain processing when they discovered that TLR5 is co-ex-
pressed with neurofilament-200, a marker of Ab fiber neurons
of the dorsal root ganglia (DRG) long associated with pain ampli-
fication under inflammatory or injury conditions (Xu et al., 2015).The current study finds that an interaction between HMGB1
and TLR5 activates the proinflammatory signaling cascade,
leading to pain hypersensitivity. We took a tripartite approach
to investigate this interaction both in vitro and in vivo. First, we
demonstrated that the downstream signaling pathway of the
HMGB1-TLR5 interaction is MyD88 dependent. Upon TLR5 acti-
vation by HMGB1, the nuclear factor kB (NF-kB) p65 subunit
translocates from the cytosol to the nucleus, resulting in the tran-
scription and release of proinflammatory cytokines and nitric
oxide (NO) in the extracellular milieu of engineered and primary
peripheral blood mononuclear cells (PBMCs). In PBMCs, both
HMGB1 and flagellin (the classical TLR5 agonist) induced NO
production, and the effects were significantly suppressed by
the co-application of TH1020, a TLR5-specific inhibitor (Yan
et al., 2016), thereby further supporting a role for HMGB1 as a
TLR5 agonist. Second, we characterized this interaction bio-
physically using fluorescence polarization and solution nuclear
magnetic resonance (NMR) spectroscopy, which revealed that
the C-terminal acidic tail region of HMGB1 is critical for binding
to the extracellular domain of TLR5 in vitro. Third, we demon-
strated the functional role of this interaction in an animal
model. Subcutaneous injection of HMGB1 induced allodynia
(i.e., decreased pain threshold) in rats, which was attenuated
by the application of the TLR5-specific inhibitor TH1020. Taken
together, our study identifies HMGB1 as a TLR5 ligand that acti-
vates the downstream proinflammatory signaling cascade with
the functional consequence of pain.
RESULTS
HMGB1 Activates TLR5 Signaling In Vitro
To investigate the cytokine-like effect of HMGB1 in TLR acti-
vation, we expressed and purified three different forms of
HMGB1 from Escherichia coli. The purified HMGB1 protein
was applied to HEK293 cells overexpressing various human (h)
TLRs (HEK-hTLRs). TLR activation was determined by a previ-
ously established secreted embryonic alkaline phosphatase
(SEAP) signaling assay (Cheng et al., 2015). Interestingly, we ob-
tained significant stimulation of hTLR2, hTLR4, and hTLR5 by
full-length rat HMGB1 (Figure 1A) in HEK cells. By contrast, no
NF-kB-driven SEAP activation was observed upon the addition
of HMGB1 to HEK-hTLR3, HEK-hTLR7, HEK-hTLR8, or HEK-
hTLR9 cells (Figure S1A). We also probed the involvement of
the RAGE receptor in hTLR-overexpressing cells, as HMGB1 is
a known RAGE ligand. We did not observe any SEAP activation
in the HEK-hTLR2, HEK-hTLR4, or HEK-hTLR5 cells by the
RAGE ligand AGE-BSA (Figure 1A). These results, while suggest-
ing the absence/inactivity of the RAGE receptor in HEK-hTLR
cells, encouraged us to perform several control experiments to
probe HMGB1-mediated TLR5 activation. First, we confirmed
that no bacterial lipopolysaccharide (LPS) contamination was
present in the HMGB1 protein sample using the standard chro-
mogenic limulus amebocyte lysate assay (van Zoelen et al.,
2009). Second, we performed experiments in the presence of
polymyxin B (PMB), a known inhibitor of an LPS-inflammatory
response (Sakharwade et al., 2013). PMB effectively neutralized
LPS-mediated activation of TLR4 in HEK-hTLR4 cells but
failed to inhibit HMGB1-mediated TLR4 and TLR5 activation inCell Reports 17, 1128–1140, October 18, 2016 1129
HEK-hTLR4 and HEK-hTLR5 cells (Figures S1B and S1C), ruling
out LPS contamination as the cause of the observed proinflam-
matory effects. Next, we utilized wild-type (WT) HEK cells, which
express only low endogenous levels of TLRs. As shown in Fig-
ure 1A, we did not observe any activation of the SEAP reporter
in these cells upon stimulation by TLR2, TLR4, TLR5, and
RAGE ligands. Additionally, HMGB1 did not exhibit any NF-kB
activation in these cells. These results confirm the absence of
RAGE in HEK cells and highlight the involvement of TLR2,
TLR4, and TLR5 in HMGB1-mediated NF-kB activation.
Previous studies with RAW 264.7 cells suggested a role for
HMGB1 in activating NF-kB signaling through TLR2 and TLR4
receptors, with RAGE playing only a minor role (Park et al.,
2004). Others have reported that RAW 264.7 cells lack a func-
tional TLR5 (Means et al., 2003). We probed the activating effect
of TLR ligands along with HMGB1 in RAW 264.7 cells by per-
forming an NO assay as previously described (Csakai et al.,
2014). HMGB1 significantly activated the NF-kB-driven induc-
ible NO synthase (iNOS) gene in comparison to other TLR ligands
such as PAM2 (TLR2), LPS (TLR4), and the RAGE ligand
AGE-BSA (Figure 1B). To further probe the role of HMGB1 in acti-
vating RAGE, TLR2, and TLR4 in RAW 264.7 cells, we utilized
oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocho-
line (oxPAPC), an inhibitor specific to both TLR2 and TLR4
(Erridge et al., 2008). oxPAPC efficiently inhibited both PAM2-
and LPS-induced activation of TLR2 and TLR4 (Figure 1B)
without significant cellular toxicity at 30 mg/mL (Figure S2A).
Additionally, an anti-RAGE neutralizing antibody (NAb) signifi-
cantly decreased the level of iNOS activity induced by AGE-BSA
in RAW 264.7 cells. The inhibition of PAM2- and LPS-induced
TLR2 and TLR4 signaling by oxPAPC was also demonstrated
in HEK-hTLR2 and HEK-hTLR4 cells (Figures S2B and S2C),
where a significant decrease in NF-kB-mediated SEAP activa-
tion was observed at a 30 mg/mL dose. No such oxPAPC inhib-
itory effect was observed in HEK-hTLR5 cells treated with
200 mg/mL flagellin (Figure S2D). Together, these results indi-
cated that HMGB1 activates SEAP signaling in hTLR5-overex-
pressing HEK cells but not WT HEK cells. Furthermore, in com-
parison to previous in vitro results, RAW 264.7 cells that lack
functional TLR5 still display HMGB1-mediated activation of
TLR2 and TLR4, with RAGE playing a minor role.
HMGB1 Activates TLR5 Signaling via the MyD88
Pathway
To dissect themechanism of TLR5 activation in HEK-hTLR5 cells
by full-length rat HMGB1, we utilized five independent methods
to inhibit the signaling cascade at different stages of the down-
stream NF-kB signaling pathway. First, an anti-TLR5 NAb was
used to block direct activation by flagellin or HMGB1, followed
by a small-molecule inhibitor of MyD88 (Davis et al., 2006) and
a peptide inhibitor of the TIRAP pathway (Brown and McIntyre,
2011) to target the downstream adaptor proteins (Figure 2).
Finally, two more inhibitors, triptolide (NF-kB inhibitor) (Qiu
et al., 1999) and TH1020 (TLR5 inhibitor) (Yan et al., 2016),
were applied to decipher how HMGB1-TLR5 signaling activates
the NF-kB-driven proinflammatory pathway.
Anti-TLR5 NAb caused almost complete inhibition of both
flagellin- and full-length rat HMGB1-induced activation of1130 Cell Reports 17, 1128–1140, October 18, 2016TLR5 signaling in HEK-hTLR5 cells, supporting an interaction
between HMGB1 and TLR5 (Figure 2A). Furthermore, the
MyD88 peptide inhibitor also displayed significant inhibition of
TLR5 activation by flagellin and HMGB1 at 25 mM (Figure 2B),
while the TIRAP peptide inhibitor failed to prevent signaling
(Figure 2C). Neither inhibitor showed any cellular toxicity (see
Figure S2E for MyD88 inhibitor data; TIRAP inhibitor data not
shown). Additional control experiments showed that anti-TLR4
NAb and TIRAP peptide inhibitor suppressed TLR4 activation
by HMGB1 (Figure S2F) or LPS (Figure 2C) in HEK-hTLR4 cells.
Thus, our results are consistent with previous reports of TLR4
activation by HMGB1 (Yang et al., 2010) or LPS (Chow et al.,
1999).
Next, a dose-dependent inhibition of HMGB1-activated HEK-
hTLR5 cells was observed with TH1020 (Figure 2D). Control
experiments confirmed that TH1020 also inhibited flagellin-
induced TLR5 activation in HEK-hTLR5 cells as reported
previously (Yan et al., 2016) with no apparent cytotoxicity (Fig-
ure S2G). Furthermore, NF-kB activation was inhibited by treat-
ing HMGB1-stimulated HEK-hTLR5 cells with triptolide, a
small-molecule inhibitor of NF-kB (Qiu et al., 1999) (Figure 2E).
As a positive control, the same assay was also performed on
flagellin-treated HEK-hTLR5 cells (Figure 2E) and showed a
similar inhibitory effect. A summary of all treatments targeted
at downstream adaptor proteins is presented in Figure 2F.
Finally, we tested the activation of the NF-kB pathway in
Jurkat T cells stably transfected with a GFP NF-kB reporter
gene (Figure 3). Because these cells do not respond to TLR2
and TLR4 agonists but do respond to flagellin (TLR5 agonist)
(Thibault et al., 2009), they were used as a valid platform to
demonstrate the HMGB1-TLR5 interaction. Flow cytometric
analysis showed a clear shift in the GFP signal of Jurkat cells
treated with flagellin and HMGB1 compared to all other treat-
ments with TLR/RAGE ligands (TLR2, PAM2/PAM3; TLR3,
poly(I:C); TLR4, LPS; TLR7/TLR8, R848; and RAGE, AGE BSA),
which showed no change in GFP signal.
HMGB1 Enhances NO Production in Primary Cells
We employed a previously reported NO assay (Csakai et al.,
2014) on primary rat PBMCs. Treatment of the PBMCs with
flagellin and HMGB1 resulted in significant production of NO
that was decreased upon TH1020 treatment at 0.75 and
1.5 mM (Figure 4A).
HMGB1 Activates NF-kB Translocation and
Proinflammatory Cytokine Production
Activation of the TLR5 receptor by flagellin from both Gram-pos-
itive and Gram-negative bacteria culminates in NF-kB transloca-
tion to the nucleus and production of proinflammatory cytokines,
such as tumor necrosis factor a (TNF-a) and IL-8 (Hayashi et al.,
2001). Western blot analysis of the nuclear translocation of the
p65 subunit of NF-kB was performed in HMGB1-treated HEK-
hTLR5 cells. qRT-PCR and ELISA assays were performed in a
human monocytic leukemia cell line, THP-1, to monitor proin-
flammatory cytokine production.
Western blot results showed a significant increase of the p65
subunit in the nucleus upon exposure to flagellin and HMGB1
compared to the untreated cells (Figure 4B). This result supports
Figure 2. HMGB1 Activates TLR5 Signaling through the MyD88 Pathway
(A–E) HEK-hTLR5 cells were treated with HMGB1 or flagellin followed by addition of anti-TLR5 neutralizing antibody (anti-TLR5 NAb) (A), MyD88 inhibitor (B),
TIRAP inhibitor peptide (C), TH1020 (a TLR5 inhibitor) (D), or triptolide (an NF-kB inhibitor) (E) for 24 hr.
(F) Schematic overview of the treatments of anti-TLR5 NAb, MyD88 inhibitor, TH1020, and triptolide in the TLR5 signaling cascade. NF-kB activation was
evaluated by SEAP secretion in the culture supernatant by the QUANTI-Blue SEAP reporter assay. Both HMGB1 (1 mg/mL) and flagellin (200 ng/mL) strongly
activated NF-kB-mediated SEAP signaling, followed by dose-dependent inhibition by anti-TLR5 NAb, MyD88 inhibitor, TH1020, and triptolide, but not the TIRAP
inhibitor peptide. For the TIRAP inhibitor assay, we confirmed that the peptide decreased SEAP secretion from LPS-treated HEK-hTLR4 cells in a dose-
dependent manner. All data are presented as mean ± SD; n = 3.
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Figure 3. HMGB1 Activates Downstream
NF-kB Signaling through TLR5
Flow cytometric analysis of NF-kB activation in
human Jurkat TLR5-sensitive T cells with various
TLR ligands: (A) PAM2 and PAM3 for TLR2, (B)
poly(I:C) for TLR3, R848 for TLR7/TLR8, (C) LPS for
TLR4, flagellin for TLR5, (D) AGE-BSA for RAGE,
and HMGB1 for TLR5. HMGB1 and flagellin both
triggered NF-kB activation upon binding to TLR5,
while other ligands failed to activate NF-kB. The
human Jurkat T cell line was stably transfected
with a GFP-labeled NF-kB reporter gene. Cells
sensitive to TLR5 activation were sorted using
a MoFlo cytomation fluorescence-activated cell
sorter. 10% of activated cells were collected and
used for this experiment.the requirement of NF-kB translocation for downstream proin-
flammatory cytokine release.
To investigate the mRNA expression levels of downstream
proinflammatory cytokines, qRT-PCR was performed on post-
ligand-stimulated HEK-hTLR5 cells (Gewirtz et al., 2004; Cham-
berlain et al., 2012). TLR5 activation by flagellin led to significant
upregulation of the mRNA levels for both TNF-a and IL-8 in
comparison to untreated cells (Figure 4C). Similarly, treating
the cells with full-length HMGB1 at 0.5 or 1 mg/mL concentra-
tions also resulted in a significant increase in the mRNA levels
of both TNF-a and IL-8.
Furthermore, the production of TNF-a and IL-8 as proinflam-
matory cytokines upon TLR5 activation by HMGB1 was deter-
mined by two sets of ELISA experiments in the THP-1 cell line.
In the first set (Figure 4D), TLR2, TLR4, and TLR5 were stimu-
lated by their respective ligands (PAM2, LPS, and flagellin or
full-length rat HMGB1, respectively). We then coupled these
TLR stimulations with varying concentrations of oxPAPC to
measure TNF-a release upon TLR2 and TLR4 inhibition. With
30 mg/mL oxPAPC, we observed a significant inhibition of
TNF-a secretion upon PAM2- and LPS-mediated TLR2 and
TLR4 activation but no effect on flagellin-induced TLR5 stimula-
tion, suggesting the specificity of oxPAPC to TLR2 and TLR4.
Stimulation of cells with HMGB1 displayed a significant release
of TNF-a, which was not completely blocked by 30 mg/mL
oxPAPC (Figure 4D). This result suggested that although
HMGB1’s signaling through TLR2 and TLR4 was inhibited by
30 mg/mL oxPAPC, contributions from other putative receptors
(i.e., RAGE and TLR5) were still present.
In the second set, the role of TLR5 andRAGE in HMGB1-medi-
ated cytokine release in THP-1 cells was determined. Treatment
of THP-1 cells with AGE-BSA to activate RAGE, and HMGB1 to
activate TLRs and RAGE, caused significant TNF-a release
in comparison to untreated cells (Figure 4E). Using 30 mg/mL1132 Cell Reports 17, 1128–1140, October 18, 2016oxPAPC, we observed an 50% inhibi-
tion of TNF-a release in HMGB1-stimu-
lated samples due to the inhibition of
TLR2 and TLR4. Furthermore, signifi-
cant inhibition of TNF-a secretion was
observed upon addition of an anti-TLR5
NAb, thereby confirming the role ofHMGB1 in activating immune signaling through TLR5. Addition-
ally, combining an anti-RAGE NAb with oxPAPC or anti-TLR5
NAb samples did not exhibit any significant inhibition in TNF-a
level. Furthermore, no apparent cellular toxicity was observed
for samples subjected to various treatment conditions (Fig-
ure S2H). Similar trends were observed for IL-8 secretion in
THP-1 cells. When cells were treated with an anti-TLR5 NAb, sig-
nificant inhibition of IL-8 production was observed in comparison
to the HMGB1-activated and oxPAPC-inhibited cells (Figure 4F).
C-Terminal Tail of HMGB1 Interacts with TLR5
To determine the binding affinity and structural basis of the
HMGB1-TLR5 interaction, fluorescence anisotropy and NMR
spectroscopy were performed on the complex of full-length
HMGB1 and the recombinant zebrafish Danio rerio ortholog of
TLR5 (drTLR5) extracellular domain (ECD). We utilized drTLR5
because the functionally active mammalian TLR5 cannot be pu-
rified in sufficient quantities. In the fluorescence anisotropy
assay, we first validated binding between HMGB1 and the
TLR4 accessory protein MD-2 (positive control) with an apparent
binding constant (Kd) of 0.6 ± 0.2 mM (Figure S3A), which agrees
with previously reported results (Yang et al., 2015). Next,
unlabeled drTLR5 ECD was titrated into fluorescein-labeled
HMGB1 (Figure S3B). Using a 1:1 protein-ligand model, a Kd of
2.9 ± 0.6 mM was obtained for HMGB1-drTLR5 interaction. The
quality of the fit was demonstrated by an adjusted R2 value
of 0.98. By contrast, no interaction was observed between
HMGB1 and the control protein, bovine serum albumin.
The binding mode of the drTLR5-HMGB1 interaction was
further elucidated by solution NMR spectroscopy. 1H-15N heter-
onuclear single quantum correlation (HSQC) spectra were
collected with the full-length 15N-uniform-labeled HMGB1 (apo-
HMGB1) and 15N-uniform-labeled HMGB1 bound to drTLR5
ECD. Sequence-specific backbone residue assignments of
Figure 4. TLR5-HMGB1 Interaction Produces NO in Primary Cells and Releases Proinflammatory Cytokines in THP-1 Cells
(A) Normalized iNOS activation folds of the inhibitory effect of TH1020 on flagellin- and HMGB1-induced TLR5 activation in rat primary PBMCs. *p < 0.05 for
TH1020 relative to the positive controls. Values are mean ± SD; n = 2.
(B) Western blot analysis of HEK-hTLR5 cells treated with flagellin (200 ng/mL) or HMGB1 (1 mg/mL) for 4 hr at 37C, 5% CO2, shows significant translocation of
p65 (NF-KB subunit) from the cytosolic to nuclear fraction. GAPDH and lamin B are shown as internal controls.
(C) In HEK-hTLR5 cells, HMGB1 and flagellin induced IL-8 and TNF-amRNA expression at 16 hr post-treatment. Changes in gene expression levels are shown
relative to untreated controls. IL-8 and TNF-a gene expression levels were determined using the expression ratio of the gene of interest to GAPDH.
(D) ELISA assays conducted by inhibition of TLR2 and TLR4 in THP-1 cells by oxPAPC. oxPAPC displayed significant inhibition of TNF-a release in THP-1 cells
upon activation by PAM2, LPS, and HMGB1, whereas no inhibition was observed for flagellin-induced TNF-a release in comparison to uninhibited cells.
(E) Treatment of THP-1 cells by AGE-BSA andHMGB1 induced significant TNF-a secretion. Inhibition of TLR2 and TLR4 by oxPAPC alongwith HMGB1 treatment
displayed significant inhibition of TNF-a release. To elucidate the roles of TLR5 or RAGE in HMGB1-mediated NF-kB signaling, we combined anti-TLR5 NAb
alone or with anti-RAGE NAbwith oxPAPC and HMGB1 samples. Significant inhibition of TNF-a release was observed with anti-TLR5 NAb, suggesting the role of
TLR5 in mediating TNF-a release via HMGB1. See also Figure S2H.
(F) oxPAPC (inhibitor of TLR2 and TLR4) and oxPAPC/TLR5-NAb displayed significant inhibition of IL-8 release in THP-1 cells upon activation by HMGB1. qPCR
and ELISA data are presented as mean ± SD; n = 3. *p < 0.05 (unpaired Student’s t test).
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Figure 5. Characterization of Binding Sites of HMGB1 with TLR5
(A) Two-dimensional 1H-15N HSQC spectra of 15N-uniformly labeled CBP-HMGB1 (blue) superimposed on 15N-uniformly labeled CBP-HMGB1 bound with
unlabeled TLR5 ECD (red). Changes in chemical shifts, peak broadening, and sharpening upon TLR5 addition are marked as dotted boxes, subsets 1–4. The
subsets include HMGB1 N-terminal residues, the basic linker region (residue 170–187), and A- and B-box helices. The ‘‘random coil region’’ of the spectra
(subset 3, 1H: 8.1–8.6 ppm; 15N, 120.5–123.5 ppm) has the largest chemical shift changes upon TLR5 ECD addition. All spectra were collected in 800MHz proton
frequency at 25C using 84 mM of each protein at pH 7.8. See also Figure S4.
(B) HMGB1 sequence highlighting chemical shift changes upon TLR5 addition. Different segments of the protein are shown by arrows.
(legend continued on next page)
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Figure 6. TLR5-HMGB1 Interaction Causes
Allodynia In Vivo
(A) Dose-dependent effect of subcutaneous flagellin
on hindpaw withdrawal thresholds to von Frey
hairs (allodynia); n = 4/group. Data represent
mean ± SEM.
(B) Dose-dependent effect of subcutaneous TLR5
antagonist TH1020 on HMGB1-dependent allo-
dynia (10 mg, subcutaneous); n = 6 per group. Data
represent mean ± SEM. **p < 0.01, ***p < 0.001
(relative to 0 mg); yyp < 0.01, yyyp < 0.001 (relative
to 3 mg); ##p < 0.01, ###p < 0.001 (relative to
baseline [BL]).the apo-HMGB1 were performed using previously published
HMGB1 spectra (Watson et al., 2007) (Table S1; Figures S4A
and S4B). We observed various chemical shift changes in the
HMGB1-drTLR5 complex spectra (Figure 5A, inset 1-4). The
random coil region of the spectra (1H, 8.1–8.6 ppm; 15N, 120.5–
123.5 ppm) corresponding to the ‘‘acidic tail’’ (residues 185–
215) of HMGB1 showed maximum chemical shift broadening
and peak shifts, suggesting that it was the primary binding site
of HMGB1 and drTLR5 in solution (Figure 5A, inset 3). The chem-
ical shifts broadening pattern of this spectra also suggests that
the tail region lacks a defined secondary structure in its ligand-
bound state (Figure 5A, inset 3). Further, residues from the linker
connecting the B box to the tail, such as Ala170, Val175, Ala177,
Lys179, Lys181, andLys184, toGlu187 (Figure 5A, insets 3 and 4)
of the tail region were also broadened and sharpened, and some
shifted, indicating potential interaction sites with drTLR5. Simi-
larly, the chemical shifts of the Asp90-Pro91-Asn92-Ala93 resi-
dues in the spectra (Table S1) suggested a previously reported
type-I b turn at the beginning of the B-box of HMGB1. Apart
from the tail and basic linkers, some residues of the N terminus,
A-box and B-box were also affected by drTLR5 interaction (Fig-
ure 5A, insets 1 and 2). All residues shifted upon drTLR5 addition
are highlighted in the HMGB1 amino acid sequence shown in
Figure 5B.(C) HSQC spectra of the 1:1 complex of TLR5 ECD and 15N tailless HMGB1 (red) superimposed onto the 15
HMGB1 tail is the primary TLR5 ECD interaction site. See also Figure S4.
(D) HEK-TLR5 cells treated with flagellin (200 ng/mL) and full-length HMGB1 (1 mg/mL) showed TLR5-induced
(1–10 mg/mL) could not do so. Data are presented as mean ± SD; n = 3. *p < 0.05 (unpaired Student’s t tes
Cell RepoThe HSQC spectra of 1:1 and 1:2 (mol:
mol) HMGB1-drTLR5 interactions were
essentially the same as Figure 5A (red
spectra), showing no new peak shift or
new peak appearance in HMGB1 (data
not shown). To confirm our conclu-
sion that the acidic tail of HMGB1 plays
a critical role in this interaction, we
collected HSQC spectra of the 1:1
complex of drTLR5 and 15N-tailless
HMGB1 (red spectra) and compared
with the 15N-tailless HMGB1 spectrum
(green spectra) (Figure 5C). Both spectra
overlapped significantly on each other,
confirming that tailless HMGB1 doesnot interact with drTLR5. The importance of the C-terminal
tail region of HMGB1 in binding and activating TLR5 signaling
was also confirmed by in vitro SEAP assay (Figure 5D).
We found that TLR5 is activated by full-length HMGB1 or flagellin
(positive control), but not by the tailless mutant of HMGB1.
HMGB1-Mediated TLR5 Signaling Causes Allodynia
In Vivo
To test whether TLR5 was functionally expressed at peripheral
nerve terminals and could transduce nociceptive signals,
flagellin was subcutaneously administered into the hindpaw of
rats. Flagellin induced dose-dependent allodynia within 2 hr,
which resolved within 24 hr of administration (Figure 6A). This
study demonstrated a functional role of TLR5 via this route of
administration, providing a rationale to explore the activation/in-
hibition of TLR5 by HMGB1 and TH1020 in vivo. Next, functional
activation of TLR5 by HMGB1 was assessed, where TH1020
(0 [vehicle control], 0.3, or 1 mg) was subcutaneously adminis-
tered into the hindpaw of rats, followed by 10 mg HMGB1, which
was subcutaneously administered into the same site 30 min
later. Compared to baseline, HMGB1 induced significant allo-
dynia (Figure 6B), which was attenuated by TH1020. Post hoc
tests did not reveal a significant difference between these two
doses of TH1020.N tailless HMGB1 spectra (green) confirms that the
SEAP activation, while the tailless HMGB1 mutant
t) relative to untreated cells.
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DISCUSSION
The recognition of DAMPs and PAMPs by various TLRs is a
critical determinant of its immunomodulatory properties in neu-
roinflammation. Given the fact that HMGB1 has been shown to
activate multiple TLRs (Park et al., 2004), we were motivated to
further examine what other receptors are involved in HMGB1-
induced activation of inflammatory signaling apart from RAGE,
TLR2, and TLR4. Here, we successfully characterized HMGB1
as a TLR5 ligand (Figures 1 and 5) and demonstrated HMGB1-
induced TLR5 activation is NF-kB driven (Figures 2 and 3)
and releases downstream proinflammatory cytokines (Figure 4)
Notably, we also showed that activation of peripheral TLR5
by HMGB1 and flagellin induces pain following subcutaneous
administration in rats (Figures 6A and 6B).
Our findings raised the question why TLR5 has been over-
looked previously in the HMGB1-mediated TLR signaling. Previ-
ously, Means et al. showed that the functional expression of
some TLRs including TLR5 was absent in the widely used plat-
form cell lines such as RAW 264.7 murine macrophages, murine
bone-marrow-derived dendritic cells (DCs), and resident/thio-
glycollate peritoneal macrophages (Means et al., 2003). Also it
was reported that in endometrial epithelial cell lines and gastric
epithelial cell lines (MKN45) the proinflammatory role of TLRs
is predominantly via TLR5 rather than TLR2 or TLR4 (Young
et al., 2004), despite the expression of TLR2 and TLR4 in these
cells. As a result, the downregulation or a lack of functionally ex-
pressed TLR2 and/or TLR4 can explain the ability of HMGB1 to
interact with TLR5 to exert its proinflammatory effects. Similarly,
Ji and coworkers showed expression of TLR1–TLR9 in mouse
DRG neurons but reported the unique distribution pattern of
TLR5 among other TLRs in sensory neurons with Ab fibers
(Xu et al., 2015).
To highlight the need of probing the functional expression of
TLR5 receptor in different cell lines, we performed this study in
a variety of cell lines, including human T lymphocytes, human
monocytes, engineered TLR HEK cells, and primary PBMCs
(Figures 1, 2, 3, and 4). Altogether, these cell-based assays illus-
trated the ability of extracellular HMGB1 to amplify the proinflam-
matory signaling cascade through TLR5, which can be blocked
partially by TH1020 inhibitor (Figure 4A). During the NF-
kB-induced cytokine release, elevated levels of downstream
effectors, such as TNF-a, IL-8, and iNOS (Figure 4), with negli-
gible cytotoxicity (Figure S2), were observed, confirming the
immunostimulatory effects of HMGB1 when bound to TLR5.
Structurally, HMGB1 is composed of three domains: A-box,
B-box, and the 30-residue C-terminal acidic tail primarily
composed of aspartic acid and glutamic acid residues (Watson
et al., 2007). The A- and B-box domains of HMGB1 have been
characterized and their role in DNA bending elucidated (Teo
et al., 1995), but the structure and function of the acidic tail in
modulating immune signaling by TLRs are poorly understood
(Watson et al., 2007; Banerjee et al., 2010). Our NMR data sug-
gest that the C-terminal acidic tail (residues 185–215), the basic
linker-region (residues 170–184), a few residues of the N termi-
nus, and the A-box (residues 14–83) and B-box (residues 88–
164) of full-length HMGB1 are critical for binding and activation
of TLR5 by HMGB1 (Figure 5). Although a few residues of the1136 Cell Reports 17, 1128–1140, October 18, 2016A- and B-boxes of the HMGB1 tailless mutant show significant
chemical shift perturbation, the rest of the residues in these
domains are almost structurally identical with the full-length
protein (Figure S4A, green labels; Table S1), confirming that
the tail region is primarily interacting with the drTLR5 ECD. Due
to the inherent challenge to express and purify the highly acidic
tail region of HMGB1, we do not have the evidence that supports
if the C-terminal tail of HMGB1 alone is sufficient to activate the
TLR5 signaling cascade. Nonetheless, our SEAP assay results
using a tailless mutant of HMGB1 clearly demonstrate that
the tailless mutant is indeed unable to trigger TLR5 activation
(Figure 5D).
HMGB1 plays a role at the brain-immune interface, where
binding of HMGB1 to the RAGE receptor leads to activation of
NF-kB, ERK1/2, p38, and SAPK/JNK kinases during neurite
outgrowth (Hori et al., 1995). Glial activation via TLR2 and
TLR4 signaling results in production of NF-kB-driven proinflam-
matory cytokines/chemokines, contributing to the initiation and
maintenance of pain hypersensitivity (Ren and Dubner, 2010;
Grace et al., 2014). Adding to this list, this study shows that sub-
cutaneous HMGB1 and flagellin can signal through TLR5 and
create pain amplification in vivo (Figures 6A and 6B). These
results can be explained by two possible mechanisms. As Ab-
fiber neurons express TLR5 (Xu et al., 2015), they may be
directly engaged by HMGB1 or flagellin to mediate mechanical
allodynia. A complementarymechanismmay also involve activa-
tion of peripheral innate immune cells that express TLR5, leading
to release of inflammatory mediators that sensitize peripheral
terminals of sensory neurons (Takeuchi and Akira, 2010; Ren
and Dubner, 2010). These data extend a prior report that allody-
nia induced by peripheral nerve injury is attenuated in Tlr5/
mice (Stokes et al., 2013) by demonstrating a fundamental role
for TLR5 in nociception and identifying HMGB1 as an endoge-
nous TLR5 ligand that may mediate nociceptive hypersensitivity
(Grace et al., 2014).
In conclusion, our results support the ability of HMGB1 in acti-
vating TLR5-mediated proinflammation of which the C-terminal
tail region of HMGB1 plays an important role in binding the
TLR5 receptor. Additional evidence suggests a noceceptive
role of TLR5 in the development of chronic pain, of which allody-
nia can be a symptom. Thus, the HMGB1-TLR5 interaction could
provide a novel therapeutic target for the development of
new pain management strategies (Grace et al., 2014; Ji et al.,
2014).EXPERIMENTAL PROCEDURES
QUANTI-Blue SEAP Assay
HEK293 cells stably transfected with human TLRs 2–5 and 7–9 (HEK-hTLR)
(InvivoGen) with an inducible SEAP reporter gene were cultured in 200 mL
DMEM supplemented with 10% fetal bovine serum (FBS), 1% penicillin/strep-
tomycin, and 1% L-glutamine (complete growth medium). Briefly, cells
were seeded at 70,000 cells per well in 96-well plates (Thermo Scientific)
and incubated for 24 hr at 37C in complete growth medium. The media was
removed from the 96-well plate and replaced with DMEM supplemented
with 10% FBS (neither 1% penicillin/streptomycin nor 1% L-glutamine) and
treated with the appropriate concentration of compounds. Then the cells
were incubated overnight at 37C for 18–24 hr. To detect SEAP activity,
20 mL media was removed from each well and transferred to a transparent
96-well plate containing 180 mL QUANTI-Blue reagent (InvivoGen) and incu-
bated at 37C (in the dark) for 30 min to 2 hr. See the Supplemental Experi-
mental Procedures for more details regarding this procedure.
NO Activation Assay with RAW 264.7 Cells
RAW264.7 cells were seeded at 70,000 cells/well in a 96-well plate with RPMI-
1640 medium (10% FBS, 1% L-glutamine, and 1% penicillin/streptomycin)
(complete growth media) and incubated at 37C over night. The next day,
the media was replaced with unsupplemented RPMI media followed by the
treatment of appropriate concentration of compounds. On day 3, 90 mL media
was transferred to a black 96-well plate, and 10 mL 0.05-mg/mL 2, 3-diamino-
napthalene (Sigma-Aldrich) in 0.62 M HCl was added to the media. The plate
was covered in aluminum foil and shaken at room temperature for 15 min,
and data were collected by a Beckman Coulter DTX 880 Multimode detector
plate reader. See the Supplemental Experimental Procedures for additional
details.
Peptide Synthesis
The TIRAP inhibitor peptide was synthesized by a CEM Liberty microwave-
assisted peptide synthesizer using standard solid-phase Fmoc chemistry.
The Fmoc-protected amino acids (0.5 mmol), HATU (1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate)
(0.5 mmol), and DIPEA (N,N-Diisopropylethylamine) (0.5 mmol) in 4 mL DMF
(N,N-Dimethylformamide) were mixed with Rink Amide resin (0.1 mmol) with
a substitution level of 0.45 mmol/g for the coupling step. Fmoc deprotection
required 7 mL 5% piperazine and 0.1 M HOBt (1-Hydroxybenzotriazole) in
DMF. All coupling and deprotection processes were duplicated to ensure
complete loading and deprotection. The peptide was cleaved from the resin
using a water/trifluoroacetic acid (TFA)/triisopropylsilane (TIPS) cocktail of
2.5%/95%/2.5% for 1 hr. Chilled Et2O was used to precipitate the peptide.
The peptide was purified by reverse phase high-performance liquid chroma-
tography (HPLC) using a semi-prep C18 column. Fractions were characterized
by MALDI mass spectrometry and lyophilized. The purity of the peptide was
analyzed by HPLC.
WST Cell Viability Assay
The supernatant from compound-treated HEK-hTLR, RAW 264.7, or THP-1
cells described above in SEAP assay was removed. The adhered cells were
treated with a 1:10 dilution of cell proliferation reagent WST-1 (Roche). Cells
were incubated at 37C until a color change was observed (30 min to 2 hr).
Data were quantified on a Beckman-Coulter DTX 880 Multimode Detector
using absorbance at 450 nm and normalized as (raw data  20% DMSO)/(un-
treated cells  20% DMSO), such that untreated cells corresponded to 100%
survival and 20% DMSO to 0% survival.
Jurkat T Cell Transfection and NF-kB GFP Reporter Assay
Human Jurkat cells (American Type Culture Collection [ATCC] TIB-152) con-
taining NF-kB/GFP reporter gene sensitized only for TLR5 ligand (flagellin)
were grown and maintained in RPMI-1640 medium containing 10% FBS and
1% penicillin/streptomycin. (See the Supplemental Experimental Procedures
for information regarding the preparation of these cells.) The TLR5-ligand-
sensitized cells were seeded in six-well plates at 1 3 106 cells per well with
3 mL complete growth medium (RPMI 1640 medium, supplemented with
10% FBS and 1% penicillin/streptomycin) and TLR ligands (200 ng/mL
PAM2 and PAM3, 5 mg/mL poly(I:C), 50 ng/mL LPS, 200 ng/mL flagellin,
5 mg/mL R848, 1 mg/mL HMGB1, and 200 mg/mL AGE-BSA) for 24 hr at
37C in a 5% CO2 humidified incubator. After 24 hr, the cells in each well
were mixed, and 200 mL cells containing medium were stained by propidium
iodide for 10 min before flow cytometry analysis performed by MoFlo Cytoma-
tion (Beckman Coulter).
Primary PBMC Isolation and NO Activation Assay
On the day of treatment, rats were anesthetized with sodium pentobarbital and
blood collected via cardiac puncture into EDTA-containing tubes. Approxi-
mately 7 mL blood was collected and 0.625 mL OptiPrep (Sigma-Aldrich)
added with gentle mixing for every 5 mL blood collected. Careful layering of
1 mL PBS over the blood/OptiPrep mixture was performed, and the cellswere then harvested by centrifugation at 1,300 3 g for 30 min at 20C. The
cell pellet was washed two times by resuspending in 10 mL cold RPMI 1640
media and centrifuging at 300 3 g for 10 min at 4C. The isolated PBMCs
were then diluted to 1 3 106 cells/mL in enriched RPMI1640 (10% FBS and
1% penicillin) and plated into 96-well plates (100 mL/well) for the NO assay.
Cells were treated with flagellin (200 ng/mL) and HMGB1 (1 mg/mL) for 1 hr
at 37C, 5% CO2, followed by treatment of TH1020 at 0.75 or 1.5 mM.
Western Blot
HEK-hTLR5 cells at 80% confluency were treated with flagellin (100 ng/mL)
and HMGB1 (1 mg/mL) in six-well plates and incubated at 37C, 5% CO2 hu-
midity. After 4 hr, supernatant was aspirated, cells were washed three times
with PBS, and total cell lysate was extracted using lysis buffer (25 mM
Tris-Cl [pH 7.5], 250 mMNaCl, 5 mMEDTA, 1%Nonidet P-40, 0.1 mM sodium
orthovanadate, 2 mg/mL leupeptin, 100 mg/mL PMSF, and protease inhibitor
cocktail tablets [Roche Diagnostics]). Cytosolic and nuclear fractions were ex-
tracted using P65 Translocation Assay Kit (Fivephoton Biochemicals) accord-
ing to the manufacturer’s instructions. Protein concentration was determined
by a Bradford assay. Samples were heated to 75C for 10 min and loaded into
a 10% Tris-glycine gel (Invitrogen). SDS-PAGE was performed in MOPS
running buffer at 175 V for 1.25 hr at 4C. Protein was transferred onto a
nitro-cellulose membrane by electroblotting and probed with the primary
p65 antibody (1:400) provided in the kit. Anti-rabbit immunoglobulin B (IgG)
and horseradish peroxidase (HRP) antibody (Cell Signaling Technology) at
1:2,000 dilutionwas used followed by visualization using enhanced chemilumi-
nescence (ECL) method. GAPDH and lamin B were used as internal controls
for cytosolic and nuclear fractions, respectively.
qRT-PCR
HEK-hTLR5 cells were seeded in six-well plates at 1 3 106 cells per well with
DMEM complete growth medium and incubated at 37C in a 5%CO2 humidity
for 24 hr. Next, the nonadherent cells and medium were aspirated and re-
placed with fresh unsupplemented medium. The cells were then treated with
200 ng/mL flagellin and HMGB1 (1 and 0.5 mg/mL), respectively, followed by
an additional 16-hr incubation. The medium was then removed and the cells
were gently washed with PBS three times. After the final washing step, 1 mL
PBS was added to each well followed by the transfer of cells into subsequent
cryotubes (1.5 mL), which were stored at 80C until qRT-PCR analysis. RNA
was extracted using the miRNeasy Mini Kit from QIAGEN. cDNA were synthe-
sized using the RT2 Easy First Strand cDNA Synthesis Kit per the manufac-
turer’s instructions. TNF-a, IL-8, and GAPDH primers were purchased from
SABiosceinces. qPCR was performed on a CFX96 Real-Time PCR detection
system (Bio-Rad) using the SYBR Green method, and the data were analyzed
by DDCt method, as previously described (Cheng et al., 2015).
ELISA
ELISA was performed using a kit from BD Biosciences to measure TNF-a and
IL-8 expression levels. THP-1 cells were seeded in six-well plates at 1 3 106
cells per well with 2 mL medium (RPMI 1640 medium supplemented with
10% FBS and 1% penicillin/streptomycin) and grown for 24 hr at 37C in a
5% CO2 humidified incubator. Prior to addition of ligands and compounds,
cells were differentiated to macrophages using 20 ng/mL per well phorbol
12-myristate 13-acetate (PMA) for 24 hr. Nonadherent cells and medium
were removed and replaced with fresh unsupplemented RPMI 1640 medium
followed by the treatment of various compounds and incubated for an
additional 24 hr. The cell culture supernatants were used for cytokine
measurement.
HMGB1 Protein Expression and Purification
The plasmids for full-length HMGB1 with N-terminal Calmodulin binding pro-
tein (CBP) and 6xHis tags (Figure S5A) were generous gifts from Prof. Kevin
J. Tracey and Prof. Patrick C. Swanson labs, respectively. Full-length proteins
were purified using previously published protocols (Li et al., 2004). In brief, the
plasmids of CBP tag 15N-HMGB1 and 6xHis tag 15N-HMGB1 full-length and
tailless were transformed into BL21(DE3) and BL21(DE3)PLys E. coli strains
for large-scale protein expression. A single colony was picked to inoculate
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each. Precultures were grown overnight at 37C in a shaker incubator and
transferred to four 1-L large cultures of LB media with the same ampicillin
antibiotic (100 mg/mL). Protein overexpression was induced by 0.4 mM
isopropyl-b-D-thiogalactopyranoside (IPTG). For CBP tag HMGB1, protein
overexpression was continued at 37C for 3 hr, while for 6xHis tag HMGB1
and tailless protein, overexpression was continued at 30C for 5–6 hr. The cells
were harvested by centrifugation at 5,000–6,000 3 g for 10 min at room tem-
perature. The cell pellet for CBP tag 15N HMGB1 (full-length) was resuspended
in 20 mL, 20 mM Tris-HCl (pH 8.6), 150 mMNaCl, and 2.5 mMCaCl2 (buffer A),
while His tag 15N HMGB1 full-length and HMGB1 tailless were resuspended in
40 mM Tris-HCl (pH 7.5) and 500 mM NaCl and stored at 80C.
Modified protocols of previously published procedures were used to purify
CBP tag 15N isotope-labeled HMGB1 (full-length), 6xHis tag 15N isotope-
labeled HMGB1 (full-length), and 6xHis tag 15N HMGB1 tailless proteins
(Figures S5B and S5C). The 15N isotope labeling method for overexpressing
protein in bacterial culture was adapted from (Das et al., 2015). (See the
Supplemental Experimental Procedures for detailed description of these
methods).
Expression and Purification of Danio rerio TLR5-N14VLR
The Danio rerio TLR5-N14VLR (drTLR5) was cloned into a pFastBac vector and
expressed and purified as described previously (Yoon et al., 2012). The drTLR5
protein was expressed in Hi5 insect cells for 3 days at 27Cwith an N-terminal
gp67 signal peptide, a C-terminal thrombin cleavage site, Strep-Tactin II, and
His6-tags. drTLR5 was purified through a His-tag affinity purification step
following by gel filtration chromatography (Superdex-200, Pharmacia) and
then cleaved overnight by thrombin to remove the tags. Cleaved drTLR5
was further purified by another His-tag affinity purification step and gel filtra-
tion in 50 mM HEPES and 100 mM NaCl (pH 7.5) buffer. The drTLR5 protein
eluted as a monomer and was concentrated to 2.5 mg/mL and stored
at 80C.
Fluorescence Anisotropy Assay
Apparent Kd values were determined by measuring the fluorescence anisot-
ropy of 200 nM or 5 mg/mL fluorescein-labeled HMGB1 as a function of
increasing concentrations of drTLR5 ECD andMD-2 proteins. The labeled pro-
tein was incubated with varying amounts of the target protein (drTLR5 ECD
and MD-2) for 30 min at room temperature in binding buffer (40 mM HEPES
[pH 7.5] and 150 mM NaCl). All measurements were made on a Horiba Fluoro-
log-3 fluorometer. The wavelengths for monitoring excitation (Ex), emission
(Em), and the emission cutoffs (Co) for fluorescein were: Ex = 494 nm, Em =
518 nm, and Co = 515 nm. Slit widths of 5 nm were used in all experiments.
Data analysis was performed as described previously (Dewan et al., 2012)
by fitting the data to a 1:1 binding model with a correction for changes in fluo-
rophore intensity caused by protein binding (OriginPro 8 SRO). Protein con-
centrations were estimated using the Bradford method (Bradford, 1976).
NMR Spectroscopy
drTLR5/HMGB1 interactions were determined by solution NMR spectroscopy
on the CBP- and 6xHis tags containing full-length and tailless 15N uniformly
labeled HMGB1 proteins ranging from 80 to 100 mM, 10% (v/v) 2H20 in
10 mM Tris HCl (pH 8.0), and 1 mM deuterated DTT. Titrations of 1:1 and
1:2 (mol/mol) drTLR5/HMGB1 (CBP- and 6xHis-tag-containing) were used.
All spectra were collected in a Varian 800-MHz or 900-MHz spectrometer
equipped with a triple-resonance cryoprobe at 25C housed at University of
Colorado Boulder and Denver campuses.
Accession Numbers
Full-length HMGB1 sequence specific backbone amide resonance assign-
ments were performed by chemical shift mapping using BioMagResBank
(BMRB) accession number BMRB: 15502 deposited by (Watson et al., 2007).
Animals
Pathogen-free adult male Sprague-Dawley rats (12 weeks old on arrival;
Envigo) were used in all experiments. Rats were housed in temperature-
controlled (23C ± 3C) and light-controlled (12-hr light/dark cycle; lights on
at 07:00 hr) rooms with standard rodent chow and water available ad libitum.1138 Cell Reports 17, 1128–1140, October 18, 2016All procedures were approved by the Institutional Animal Care and Use Com-
mittee of the University of Colorado Boulder.
Subcutaneous Injections
All drugs were administered into one plantar hindpaw, with the needle
directed between the toes, with the needle tip placed subcutaneously
into the plantar surface of the hindpaw to avoid backleak of the injectate.
To determine whether peripheral TLR5 functionally contributed to allody-
nia, 0 (vehicle control), 3, or 10 mg flagellin was administered (100 mL; saline
vehicle). To determine whether HMGB1 induced TLR5-dependent allody-
nia, 0 (vehicle control), 0.3, or 1 mg TH1020 was administered (10 mL; 3%
DMSO in saline), followed 30 min later by HMGB1 (10 mg in 10 mL; saline
vehicle).
Mechanical Allodynia
Testing was conducted blind with respect to group assignment. Rats received
at least three 60-min habituations to the test environment before behavioral
testing. The von Frey test (Chaplan et al., 1994) was performed at the distal
region of the heel in the hindpaws, within the region of sciatic innervation as
previously described (Chacur et al., 2001). Assessments were made before in-
jection (baseline), and 2, 4, 6, and 24 hr after the last injection. A logarithmic
series of ten calibrated Semmes-Weinstein monofilaments (von Frey hairs;
Stoelting) was applied to the hindpaw to define the threshold stimulus intensity
required to elicit a paw withdrawal response. Log stiffness of the hairs ranged
from manufacturer-designated 3.61 (0.40 g) to 5.18 (15.14 g) filaments. The
behavioral responses were used to calculate absolute threshold (50% proba-
bility of response) by fitting a Gaussian integral psychometric function using a
maximum-likelihood fitting method (Harvey, 1986) as described previously
(Milligan et al., 2000).
Statistical Analysis
For the animal study, mechanical allodynia was analyzed as the interpolated
50% thresholds (absolute threshold). One-way ANOVAs followed by Tukey’s
post hoc test were used to confirm that there were no baseline differences
in absolute thresholds between treatment groups. Differences between treat-
ment groups were determined using repeated-measures two-way ANOVA,
with treatment and time asmain effects, followed by Sidak’s post hoc test. Dif-
ferences between time points for HMGB1 treatment were determined using
repeated-measures one-way ANOVA, followed by Dunnett post hoc test.
p < 0.05 was considered significant.
For the in vitro cellular assay, all data presented for the SEAP and NO
assays are mean ± SD. Differences between treatment groups were deter-
mined by the unpaired Student’s t test; p < 0.05 was considered statistically
significant.
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